Phase III epalrestat trial is fully enrolled.
Based on the success of our foundational research with Perlara PBC and compassionate use trial of one patient in the US, the FDA has approved a prospective, single-center, randomized, double-blind, placebo-controlled clinical trial at Mayo Clinic for up to 40 PMM2-CDG children (ages 2-17).
Your clinical trial experience
The study is being conducted at the Mayo Clinic by experienced medical and research staff.
The science
Decades of safety data from epalrestat's use in Japan and India to treat nerve damage in adults with diabetes has supported the application for studying it’s use in children with PMM2-CDG.
Word
on the street
The results of our subject in the "pioneer" study and the approval to start the Phase III trial have attracted the attention of the scientific and business press. Join in the conversation.
"The improvement of PMM enzyme activity, and global glycosylation suggest epalrestat is a rational treatment target for PMM2-CDG and should be tested in a larger clinical trial."
Sorbitol is a severity biomarker for PMM2-CDG with therapeutic implications
Annals of Neurology
Collaborative science
Founded upon science and collaboration between researchers, clinicians and families, Maggie’s Pearl is starting a clinical trial for PMM2-CDG patients to determine if epalrestat is safe and effective.
Word on the street
Image of Mayo Clinic Rochester Minnesota, Gonda Building and part of Mayo Building from cafeteria Copyright ©2008 Michael Bonert.
You are free to share and adapt this image as per the CC BY-SA 3.0.